March 22, 2024 Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer’s Disease Testing Infrastructure read more
March 4, 2024 Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease read more
February 29, 2024 Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023 read more
January 26, 2024 Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer’s Disease Pathology read more
October 3, 2023 Ultrasensitive immunoassay technology drives blood-based biomarkers for Alzheimer’s disease read more
September 6, 2023 Serum neurofilament light chain database effective in estimating pediatric neuro issues read more
March 29, 2024 Breaking Ground in Alzheimer’s Diagnosis: Simoa® p-Tau 217 Blood Test Receives FDA Breakthrough Device Designation read more